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Treatment-Induced Brain 
Plasticity in Psychiatric Disorders
Maria Uscinska, Andrea Polla Mattiot and Silvio Bellino
Abstract
In tandem with a better-informed neurobiological model of mental illness, 
psychiatry has progressively been shaped into its current state of clinical neurosci-
ence. The traditional dichotomy of organic versus endogenous mental disorders has 
been replaced by the growing recognition that all changes in mental processes are 
accompanied by changes in structures or functions of the brain. Thus, all psychi-
atric interventions are deemed to have a biopsychosocial nature, whereby drugs in 
addition to their effect on the brain have a psychological effect, and psychothera-
pies beyond their psychological effects may alter the brain. In this view, the ultimate 
goal of any psychiatric treatment is to induce neural plasticity in a manner that 
restores the full original function and potential of the injured brain. Herein present 
chapter gives an insight into how evidence-based treatments achieve their thera-
peutic effects on the level of cerebral reorganization across a host of psychiatric 
disorders. The main theme of this work is the posited mechanism of neuroplasticity 
on neural-systems level for each treatment modality.
Keywords: therapy, drugs, treatment, psychosis, schizophrenia, depression, 
disorder, antidepressant, antipsychotic, neuroimaging, fMRI, cognitive, plasticity, 
mood stabilizers, neural correlates
1. Neural parameters of therapeutic change
Mechanisms of neuroplasticity constitute fundamental processes behind 
learning and memory, that determine the ability of neuronal systems to incor-
porate novel environmental stimuli and to make appropriate adaptive response. 
Delineating cerebral processes of recovery from an insult to the brain holds promise 
for developing more refined and novel treatment modalities to target specific areas 
of pathology. Functional neuroimaging studies provide a mean to characterize 
changes in brain function related to psychiatric interventions. Well-established in 
indexing biomarkers of psychiatric disorders, novel neuroimaging techniques are 
now used to depict patterns of neural plasticity mediating post-treatment ameliora-
tion of symptoms. Various modalities provide indices of brain activity by measuring 
cerebral blood flow or glucose metabolism including functional magnetic resonance 
imaging (fMRI), 18fluorodeoxyglucose positron emission tomography (FDG-PET), 
and 99mtechnetium hexamethylpropyleneamineoxime single photon emission 
computed tomography (99mTc-HMPAO SPECT) [see ref. 1 for a detailed review] 
One powerful imaging modality that has significantly advanced our knowledge 
in this field is the task-based functional magnetic resonance imaging (t-fMRI). 
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It consists of a paradigm defined by a functional measurement including a stimula-
tion adjusted to the brain area under investigation. The subject is required to perform 
a defined motor or sensorimotor, language or another cognitive or visual tasks in 
the MRI scanner while typically GRE T2*-weighed echo planner images (EDI) are 
rapidly acquired [for a more in-depth description of fMRI see ref. 1]. Local changes 
in cerebral blood flow (CBF) during task execution relative to resting state are used 
to infer brain regions/networks functionally involved in specific tasks. To ultimately 
determine the specificity and amount of therapy-induced neuroplasticity, multiple 
pre-, and post- therapy scans are compared against activity pattern changes in other 
active treatment groups and a no-treatment waiting-list group [2]. With this in 
mind, the next section follows with an overview of main findings associated with 
intervention-induced neuroplasticity and their interpretations.
2. Putative neuroplastic mechanisms of pharmacotherapy
Pharmacotherapy constitutes first-line treatment modality for majority of 
psychiatric disorders, and various theories exist as to how drug-induced neu-
rochemical changes reverse different psychiatric symptoms. The posited purely 
neurotransmitter-based mechanism of action postulates either increased or reduced 
synaptic concentration of a target neurotransmitter that is implicated in a given 
disorder. This model is challenged by disjunction in the timescale of the onset of 
neurochemical versus therapeutic effects, wherein the potentiation or attenuation 
of neurotransmitter function often occurs within hours of administration and the 
clinical improvement is typically seen days or weeks after [3]. In quest of new rapid-
acting agents, contemporary approaches to understanding of drug action focus on 
the role of adaptive neuroplastic processes that correlate in time with the onset of 
clinical improvement, hence are hypothesized to represent a more direct treatment 
target.
2.1 Antidepressant drugs and mechanisms of neuroplasticity
Current national and international guidelines recommend serotonin reuptake 
inhibitors (SSRIs) as first-line treatment for most patients with major depression, 
and the use of serotonin—norepinephrine reuptake inhibitors (SNRI) in patients 
resistant to the former [4, 5]. Although novel, better tolerated and more selec-
tive inhibitors of serotonin and norepinephrine reuptake are continuously being 
developed, the efficacy of tricyclic antidepressants such as amitriptyline for severe 
depression, has never been surpassed [6].
Most of currently licensed antidepressants act to enhance monoamine neuro-
transmission, where they are believed to achieve therapeutic effects by increasing 
availability of serotonin or/and norepinephrine, at least initially [7]. On the neural 
level, antidepressants normalize aberrant neural activity patterns underlying 
negative bias in affective information processing, posited to play central role in the 
etiology and maintenance of depressed state [8]. Thus, antidepressants were shown 
to attenuate hyperactivity in limbic areas of the brain (amygdala, insula, anterior 
cingulate), and enhance regulatory activity in the dorsolateral and medial prefron-
tal cortex as measured by functional magnetic resonance imaging [9, 10]. It was 
demonstrated that 7 days treatment with SSRI, citalopram, SNRI, and reboxetine 
reversed abnormal patterns of neural response to affective information, and induced 
a similar direction of change in healthy individuals [11, 12]. Noteworthy, short-term 
SSRI administration normalized amygdala hyperactivity in response to negative 
emotional stimuli prior to clinical changes in mood ratings in placebo-controlled 
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studies [13]. These findings allow to speculate that treatment-induced early reversal 
of negative emotional bias sets the scene for therapeutic recovery over time by 
reducing the influence of this key maintaining factor [14].
2.2 Antipsychotic drugs and mechanisms of neuroplasticity
Antipsychotic medication is the mainstay of effective management of psychosis 
where schizophrenia is the most prevalent among psychotic disorders. Most of 
what we know about antipsychotic drugs action is at the receptor level, where 
abnormalities in neurotransmission constitute either an excess or a deficiency of 
neurotransmitters, including dopamine, serotonin, and glutamate. Therein first-
generation drugs act as antagonists of dopamine D2 receptors and target most 
positive symptoms such as hallucinations and delusions. The receptor-binding 
profile of second-generation drugs extends beyond D2 affinity antagonism to other 
neuroreceptors including serotonin 5-HT2A in the frontal lobe, thus accounting 
for superior efficacy of these drugs in the pathophysiology of negative symptoms 
and cognitive disorganization [15, 16]. Overall, treatment response has been shown 
to be associated to the level of D2 occupancy, which is the target of all currently 
licensed antipsychotics [17]. To delineate therapeutic mechanism of clinically 
effective drugs beyond receptor level, research has focused on neural systems 
effects before and after pharmacotherapy in medication-naïve patients with first- 
episode psychosis. Functional MRI studies revealed pre-treatment functional 
alterations within frontostriatal circuitry, marked by patterns of hypoactivity 
within the dorsolateral/medial prefrontal cortex coupled with hyperactivity in the 
hippocampus and striatum [18–20]. Thus, aberrant frontostriatal circuitry might 
represent a potential system- level mechanism of psychosis and a candidate for 
treatment target with antipsychotics. Post-treatment findings lend some evidence 
to validate this model, showing increases in task-related frontal cortical activation 
in patients who underwent 12 weeks of quetiapine fumarate treatment compared 
to a drug-naive group [21, 22], and in a small group of patients with schizophrenia 
medicated with risperidone [23]. A similar study on cortical structure and function 
alterations within 1 year of psychosis onset in unmedicated schizophrenia patients 
versus patients under short-term therapy with atypical antipsychotics revealed 
a more complex relationship [20]. Although the treatment was associated with 
enhanced cognitive control and increased prefrontal, middle temporal, parietal, 
and occipital activity, it also revealed post-treatment prefrontal cortical thinning in 
the treatment group. The mechanism by which antipsychotics are associated with 
the loss of gray matter remains unclear, however neuroinflammatory models posit 
elevations in proinflammatory cytokine levels [24], microglia activation [25], and 
increased extracellular volume in white and gray matter [26]. Thus, the study adds 
to the growing literature on therapeutic mechanisms of antipsychotics, mediated by 
normalization of aberrant frontal cortical function, and suggests that caution must 
be exercised in interpreting neuroanatomical changes as being potentially deleteri-
ous to brain function.
2.3 Mood stabilizers and mechanisms of neuroplasticity
Lithium and anticonvulsants with mood-stabilizing properties (lamotrigine, 
valproate) constitute first-line drug treatment for episodes of depression and 
mania with variable inter-episode remission [27–29]. Whilst different compounds 
may differentially target specific facets of bipolar disorders, lithium is effective for 
all phases including acute depression [30]. On the neural level, functional imag-
ing studies consistently point to pre-treatment frontolimbic dysfunction during 
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cognitive control and emotion-paradigms in bipolar disorder patients [31–33]. 
Thus, abnormal emotion regulation and impaired cognition might be attributed to 
interference in cognitive control within medial prefrontal cortex though overactiv-
ity in subcortical structures (amygdala, ACC, insula), involved in emotion genera-
tion and appraisal. Findings of mood stabilizers-induced neural plasticity yield 
less consistent results due to methodological limitations that make it difficult to 
draw firm conclusions. Whilst some studies find no significant effects of pharma-
cotherapy upon functional measures of cerebral reorganization in bipolar patients 
[34–41] others reported increased task-related prefrontal cortical activity coupled 
with normalized subcortical limbic activity during emotional processing [38, 39, 
42, 43]. Typically, individuals recruited in these studies are able to tolerate medica-
tion withdrawal and washout, and therefore are likely to have a milder form of the 
disorder. Given that it is not clinically feasible to withdraw all patients with bipolar 
disorder from medication, individuals with a more severe form of the disorder are 
likely to be underrepresented in many studies and therefore findings might not be 
generalizable to the most at-need of new treatments group.
3. Putative neuroplastic mechanisms of psychotherapy
Although studies of neural parameters of therapeutic change under psychother-
apy are under-represented relative to analogous studies of medications, emerging 
literature support the thesis that changes in affect, cognition and behavior mediated 
by psychotherapy have demonstrable neuroplastic underpinnings. Since the call for 
more neuroscientifically informed approaches to psychotherapy [44], studies have 
elucidated neural mechanism of psychotherapy-induced changes in brain activity 
profiles across a range of psychiatric disorders.
3.1 Cognitive behavioral therapy and mood disorders
Psychotherapy processes appear to target maladaptive cognitive and emotional 
patterns by engaging their biological analogues that are responsive to a discrete 
mode of treatment [45]. One salient example involves re-appraisal technique under 
cognitive behavioral therapy (CBT) for depression, where patients are invited to 
re-interpret their negative perceptions of unpleasant occurrences in a more positive 
light. Mood ratings before and after re-thinking negative events revealed improved 
positive affect, mediated by elevated activity in dorsolateral and dorsomedial PFC 
coupled with decreased activity in the amygdala and orbitofrontal cortex [46]. To 
delineate CBT- induced mechanism of neuroplasticity in depression, FDG-PET 
scans before and after psychotherapy relative to paroxetine treatment were acquired 
from patients instructed to ‘avoid ruminating on any one topic’ during scanning 
[47]. Although efficacy of both treatments was comparable, differential activity 
patterns emerged in frontal and limbic regions, implying that medication and 
psychotherapy might achieve their therapeutic effects in different ways. Whilst CBT 
was associated with decreased metabolism in multiple frontal regions including 
the dorsolateral PFC together with increased activity in the hippocampus, parahip-
pocampal gyrus, and dorsal cingulate gyrus, paroxetine- induced increased PFC 
metabolism, and decrease in hippocampal, parahippocampal, posterior cingulate 
and ventral subgenual cingulate activity. This modality-specific mechanism of 
neuroplasticity posits that CBT exerts ‘top- down’ changes in cognitive processing 
in favor of engaging ventral and limbic regions, which mediate attention to person-
ally salient stimuli, whereas antidepressant drugs prompt ‘bottom-up’ disengage-
ment of ventral, frontal and limbic regions. Although this model runs counter the 
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aforementioned emotion regulation model, divergent findings might result from 
using healthy subjects in the former study and patients with depression in the latter, 
invoking the notion that brain activation results from the interaction between 
underlying brain state and treatment modality [48].
In efforts to elucidate CBT- induced neural mechanism of anxiety disorders 
functional neuroimaging study examined pre-and-post CBT brain activity patterns 
in non-medicated patients with spider phobia and healthy subjects [49]. The former 
exhibited elevated activation in the parahippocampal gyrus and right dorsolateral 
PFC prior to the treatment, which was normalized with successful group CBT 
sessions focused on exposure therapy. Given that parahippocampal gyrus medi-
ates contextual memory, authors suggested that after CBT less demand was placed 
on the dorsolateral PFC to construct a cognitive defense to the perceived threat. 
Moreover, a therapy- induced shift of activity to the ventral PFC was indexed, 
which might play a role in down-regulation of limbic activity and thereby dampen-
ing fear reaction. Collectively, these studies depict a neuroplastic model of cognitive 
behavioral therapy which posits altered engagement of dorsal prefrontal circuitry to 
down-regulate limbic and ventral prefrontal structures thereby improving affect in 
response to emotionally significant contexts.
3.2 Dialectic behavioral therapy and borderline personality disorder
Given that psychotherapy is the gold standard treatment modality for border-
line personality disorder [50], extensive research efforts focused on measuring 
brain changes induced by specific modes of therapy. To date, dialectic behavioral 
therapy is the most researched, refined and evidenced-based therapy informed by a 
deficit model in self-regulation, distress tolerance and interpersonal skills, deemed 
to arise from transaction between highly sensitive individuals and invalidating 
environments [51, 52]. DBT purports to render individuals more mindful and able 
to manage relationships effectively by incorporating the concept of dialectics and 
strategy of validation into approach focused on skills acquisition and behavioral 
shaping.
Consistent with the skills deficit model of BPD, neuroimaging evidence supports 
that acquisition of affective control strategies under DBT balances neural substrates 
of emotion regulation. One salient example indexed neural activity alterations 
under re-appraisal and reported dampened insula and ACC activity, together 
with an enhanced connectivity of the latter to medial and superior frontal gyrus, 
superior temporal gyrus, and inferior parietal cortices [53]. Notably, treatment-
induced increase in dorsal ACC activity during exposure to negative stimuli was 
associated with improvement self-reported BPD symptoms, suggesting a possible 
biomarker of improved affect regulation. In a similar study Winter et al. [54] set out 
to establish whether neural correlates of distraction might be amenable to a suc-
cessful DBT. In this view, 31 BPD patients under constant medication were scanned 
before and after a 12- week residential DBT-based treatment while performing a 
distraction task. When compared to 15 BPD control patients under non-DBT-based 
treatment or no treatment at all, and 22 healthy participants, 16 DBT responders 
exhibited attenuated activity in the right inferior parietal lobe/supramarginal 
gyrus. Notably, this pattern of brain activity was correlated with improvement in 
self-reported borderline symptom severity (ZAN-BPD). Furthermore, treatment 
was associated with a reduction in the right perigenual ACC activity and increased 
activity in these regions during distraction in the context of aversive stimuli. These 
findings might reflect a shift from emotional to more cognitive processing in the 
context of aversive stimuli, thereby suggesting an improvement in emotional 
susceptibility under DBT.
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Taken together aforementioned studies support that DBT processes target 
maladaptive emotional patterns by altering their biological analogues that are 
responsive to discrete cognitive strategies. DBT normalizes frontolimbic imbalances 
as part of the disturbed circuitry, which appear to mediate amelioration of BPD 
symptomatology. Caution must be exercised however, while interpreting results as 
medications may attenuate emotional responses in BPD patients [55], and giving 
combinations of drug subtypes makes it impossible to isolate the effect of a single 
agent.
3.3 IPT and depression
IPT is a short-term treatment that typically consists of 12–16 one-hour weekly 
sessions focused on improving interpersonal relationships. Drawing directly on 
identifiable issues between patients and therapists, it purports to instil the ability to 
make the necessary adjustments in interpersonal situations that will help to reduce 
symptoms of depression. Several imaging studies have examined biomarkers of 
cerebral reorganization induced by IPT relative to pharmacotherapy. One of them 
compared the effects of the former and venlafaxine (37.5 mg daily) on regional CBF 
using 99mTc-HMPAO SPECT in 28 drug-naive or drug-free patients with MDD 
[56]. Whilst comparative clinical improvements were mediated by elevated activity 
in the right basal ganglia in both treatment groups, patients in the IPT group also 
exhibited an increase in the right posterior cingulate activity. However, drawing 
firm conclusion from these findings is hampered by methodological issues as four 
patients with a strong preference for venlafaxine could choose the treatment, while 
one preferred IPT. Moreover, subjects in the latter evidenced greater striatal perfu-
sion, potentially reflecting design limitation. Brief duration of IPT and relatively 
low dose of venlafaxine give rise to the possibility that both treatments were sub-
optimal, thereby underscoring the engagement of limbic and paralimbic recruit-
ment in psychotherapy-induced changes reported in parallel research [56].
A similar study on the effects of IPT and paroxetine relative to healthy controls 
[57] reported results analogous to CBT effects described by Goldapple et al. [47]. 
Whilst treatment response in both groups was associated with an increase in metab-
olism in limbic and paralimbic regions (the right insula and left inferior temporal 
lobe) relative to controls, unlike CBT the effects of IPT were mediated by a decrease 
in dorsal and ventral prefrontal cortical metabolism. A follow-up study was set out 
to correlate treatment-mediated changes in brain activity patterns with ameliora-
tion in mood symptoms measured by the Hamilton Depression Rating Scale and 
the tension/anxiety and fatigue clusters of the Profile of Mood States [58]. A cohort 
of 39 patients under either paroxetine or IPT for MDD exhibited post-treatment 
reductions in ventral and dorsal frontal lobe metabolism, which was associated with 
improvements in the anxiety/somatization and psychomotor retardation symptom 
clusters. Unlike previous findings of negative correlation between activity in the 
dorsolateral PFC and improvement on global depression scores under CBT, in the 
present study alterations in dorsolateral PFC activity positively correlated with 
improvement in cognitive disturbance. These suggest that each treatment modal-
ity engages dorsolateral PFC function differently to achieve a specific therapeutic 
effect. While CBT appears to engage this region to attenuate ‘over-thinking’ in 
depression, IPT might induce it to improve general cognitive abilities.
3.4 Psychoeducation and euthymic bipolar disorder
Given that pharmacotherapy is often ineffective for treatment of residual 
depressive, dysthymic and dysphoric symptoms [59], researchers have shown 
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interest in psychoeducation in targeting emotional and cognitive processes [60–63]. 
Psychoeducation is a treatment option for bipolar disorder focused on improving 
coping strategies to manage symptoms in everyday life, compliance with medication 
to prevent thymic relapses, quality of life and social functioning [64, 65]. Whilst 
wealth of research exists to support its efficacy in clinical symptoms improvement, 
less is known how therapeutic change is achieved on the level of neural functioning.
Favre and collaborates [66] set out to index neural processes before and after 
psychoeducation therapy in 16 euthymic bipolar patients (EBP) matched against 16 
healthy subjects. Pre-treatment fMRI scans revealed reduced activity of cognitive 
control regions (bilateral inferior and left superior frontal gyri, right insula, right 
fusiform gyrus and bilateral occipital gyri) and elevated activity of emotion-related 
processing regions (bilateral hippocampus, parahippocampal gyri and the left 
middle temporal gyrus) in the treatment group. Thus, aberrant cognitive and emo-
tion processing that characterize acute episodes in bipolar disorder appear to persist 
during euthymic phase. Post-treatment clinical improvement was mediated by 
increased activity of inferior frontal gyri and a pattern of decreased activity of right 
hippocampus and parahippocampal gyrus. These findings suggest that psychoedu-
cation improves cognitive control by engaging prefrontal networks and normalizes 
generation of emotional responses by quieting activity within limbic networks.
3.5 Cognitive remediation therapy and schizophrenia
Cognitive remediation therapy (CRT) is an evidence-based treatment for neu-
ropsychological deficits in memory, attention, executive function, social cognition 
or metacognition across a host of neuropsychiatric disorders [67–69]. There is a 
growing literature focused on neurobiological changes that mediate cognitive recov-
ery under this type of intervention in patients with schizophrenia [70–73], mood 
disorders [74], mild cognitive impairment [75] and in healthy adults [76]. Majority 
of studies examined the effects of cognitive remediation on brain functioning in 
patients with schizophrenia and have amounted to several systematic reviews and 
meta-analyses [76–78]. Findings lend support to the frontal hypoactivation mecha-
nism of cognitive impairment and suggest that cognitive remediation improves 
these networks efficiency. Most commonly reported areas of post-treatment 
amelioration in efficiency involved prefrontal and thalamic regions. Meusel and 
collaborates [73] set out to describe functional correlates of cognitive remedia-
tion in patients with bipolar disorder or depression versus healthy controls. Thirty 
eight subjects completed 10 weeks of treatment and were scanned (fMRI) during 
an n-back working memory task and a recollection memory task to investigate the 
potential for change within these networks. PRE-POST improvements correlated 
with functional activation in lateral and medial prefrontal, superior temporal, and 
lateral parietal regions, suggesting neural correlates improved working memory 
under cognitive remediation.
4. Discussion
The predominant paradigm of modern psychiatry posits that advances in 
neurosciences can unravel the mysteries of mental illness. Since the 1990s were 
declared the decade of the brain, imaging evidence has taught us a great deal about 
neural correlates of symptoms expression and recovery from an insult to the brain 
[79]. Despite remarkable neuroscientific advances, specific mechanisms behind 
major mental illnesses, thus far, have not been identified [80]. Moreover, whilst 
neurotransmitters are known to mediate synaptic pathways, research has not yet 
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been able to explain any psychiatric disorder in terms of chemical imbalances 
[81]. Various reasons exist as to why neuroscience is unlikely to provide a definite 
understanding of the disordered mind. First and foremost, what is preventing 
the scientific strategy to reduce psychiatry to neuroscience is the fact that diag-
noses listed in the Diagnostic and Statistical Manual of Mental Disorders’ are not 
diseases but merely syndromes without a precise endophenotype [82]. Moreover, 
the pathways from temperamental vulnerabilities to illness cannot be understood 
without taking into account psychosocial adversities [83]. In this view, associations 
between biomarkers of pathological and treatment processes are unlikely to be 
strong or linear. Pharmacotherapy, whilst useful in severe mental disorders, it is not 
in any way curative, and psychosocial interventions continue to play an important 
role in psychiatric treatment, evoking multiple risk factors and complex interactive 
pathways to the disordered mind [84].
Research efforts in tandem with more powerful imaging techniques will further 
unravel the intricacy of cerebral organization behind pathological and treatment 
processes. Nonetheless, the scientific strategy to reduce psychiatry to neurosciences 
is hindered by a discrepancy between a clinical phenomenon and its neural sub-
strate, which is rooted in a conceptual mind and brain gap.
5. Conclusion
Long before the era of functional neuroimaging it was suggested that interven-
tion-driven changes in affect, cognition and behavior appear to have measurable 
biological analogues [85]. To date, the potential to characterize neural mechanisms 
of recovery processes have amassed vast neuroimaging data on treatment-induced 
brain plasticity. Pharmacotherapy and psychotherapy appear to engage neural 
circuits that are responsive to a discrete treatment modality. Although both have 
similar effects on brain activity patterns in patients who share the same diagnosis, 
their neural systems profile is not identical. While the former appears to act in a 
bottom- up manner on a subcortical level to regulate higher cortical structures, the 
latter acts top-down on cortical activity to subsequently impact subcortical regions. 
Although neuroimaging techniques have revolutionized our biological insight 
into recovery processes, little can be concluded about the precise neurobiological 
mechanism of these changes. The remaining question is whether these changes 
elucidate a neural mechanism of treatment action or simply reflect correlates of 
symptom amelioration. Despite methodological and theoretical limitations neuro-
imaging literature holds promise to strengthen the credibility and utility of main-
stay in psychiatric treatment, and to improve clinical decision-making.
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